Search Results - "Čižmáriková, M."

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Does the MDR1 C34354T polymorphism influence the occurrence of nausea and sexual dysfunction after paroxetine treatment in the Slovak setting?

    Does the MDR1 C34354T polymorphism influence the occurrence of nausea and sexual dysfunction after paroxetine treatment in the Slovak setting? by Vančová, Z., Dragašek, J., Čižmáriková, M.

    Published in European neuropsychopharmacology (2019)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome

    MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome by Cizmarikova, M, Wagnerova, M, Schonova, L, Habalova, V, Kohut, A, Linkova, A, Sarissky, M, Mojzis, J, Mirossay, L, Mirossay, A

    Published in The pharmacogenomics journal (01-02-2010)
    “…P-glycoprotein (PGP), the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of carcinogens and cytostatics. It has been suggested…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    P-954 - Does C3435T Genetic polymorphism of MDR1 gene influence therapeutic effectiveness of paroxetine? (preliminary results)

    P-954 - Does C3435T Genetic polymorphism of MDR1 gene influence therapeutic effectiveness of paroxetine? (preliminary results) by Vidova, Z, Cizmarikova, M, Dragasek, J, Mojzis, J, Zofcakova, S

    Published in European psychiatry (2012)
    “…Clinical efficacy of antidepressants is unsatisfactory, full remission occurs in one-third of the patients after monotherapy with antidepressant. Personalized…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: